Novo Nordisk's Sickle Cell Success Charts a New Path Beyond Blockbuster Drugs

Novo Nordisk’s share price, languishing roughly 51 percent below its 52-week high, has found a potential catalyst far removed from its flagship GLP-1 diabetes and obesity treatments. The Danish pharmaceutical giant reported unequivocally positive Phase 3 results for etavopivat, an oral therapy for sickle cell disease, marking a significant step in its strategic diversification.

The HIBISCUS trial, a 52-week randomized study involving 385 patients aged 12 and older, successfully hit both co-primary endpoints. Treatment with etavopivat reduced the annual rate of painful vaso-occlusive crises by 27 percent compared to placebo. It also significantly delayed the time to a first crisis, extending it to 38.4 weeks versus 20.9 weeks in the control group.

Perhaps more striking was the hemoglobin response. After 24 weeks, nearly 49 percent of patients receiving etavopivat achieved a hemoglobin increase of more than 1 g/dL. Only 7.2 percent of placebo patients saw a similar improvement. The therapy demonstrated a clean safety profile with no unexpected adverse events.

This clinical win arrives as Novo Nordisk actively builds a second growth pillar. The GLP-1 market, while enormous, is becoming increasingly competitive, pressuring prices. The company’s move into sickle cell disease, a chronic condition affecting an estimated eight million people globally, targets an underserved market with substantial potential. Analysts at GlobalData project etavopivat could achieve annual sales of $174 million by 2032.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

The competitive landscape appears favorable. Etavopivat is a first-in-class, once-daily oral PKR activator. Pfizer, which aimed for this market through its $5.4 billion acquisition of Global Blood Therapeutics, recently failed a Phase 3 study and withdrew its drug Oxbryta worldwide in September 2024 due to safety concerns.

Novo Nordisk secured etavopivat through its $1.1 billion acquisition of Forma Therapeutics in 2022. The drug already holds valuable regulatory designations, including Fast Track, Orphan Drug, and Rare Pediatric Disease status from the FDA, and Orphan Drug status from the European Commission.

The company plans to submit its first regulatory applications in the second half of 2026. Full study data will be presented at a future scientific conference, providing the next tangible catalyst for the stock.

Novo Nordisk at a turning point? This analysis reveals what investors need to know now.

Meanwhile, Novo Nordisk continues to support its share price through a buyback program. As part of a DKK 15 billion initiative, it has repurchased approximately 12.3 million B shares since February, worth about DKK 3.15 billion. The stock recently traded at EUR 34.56, with a Relative Strength Index of 24.6 indicating technically oversold conditions.

If etavopivat gains approval on schedule, Novo Nordisk’s rare disease segment could emerge as a meaningful new growth driver by 2027, offering investors a narrative beyond its established metabolic powerhouse.

Ad

Novo Nordisk Stock: New Analysis - 21 April

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

en | DK0062498333 | NOVO | boerse | 69226202 |